Merck KGaA (FRA:MRK) Given Average Rating of “Hold” by Analysts

Merck KGaA (FRA:MRK) has been given a consensus recommendation of “Hold” by the sixteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is €105.47 ($122.64).

MRK has been the subject of several research reports. UBS Group set a €104.00 ($120.93) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, November 26th. Nord/LB set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, January 21st. Credit Suisse Group set a €125.00 ($145.35) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, January 16th. JPMorgan Chase & Co. set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, February 5th. Finally, Barclays set a €94.00 ($109.30) price objective on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday, January 20th.

Shares of MRK stock traded down €0.40 ($0.47) during trading hours on Friday, hitting €122.35 ($142.27). 407,188 shares of the company were exchanged. The business has a 50 day moving average of €114.87 and a two-hundred day moving average of €105.05. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What is a Derivative?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.